Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure

Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. This is a retrospect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2017-10, Vol.77 (4), p.675-682.e1
Hauptverfasser:	Liu, Lucy Y., Strassner, James P., Refat, Maggi A., Harris, John E., King, Brett A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Autoimmunity Chemokine CXCL10 - metabolism Chemokine CXCL9 - metabolism Combined Modality Therapy Female Humans JAK Janus kinase Janus Kinase 1 - antagonists & inhibitors Janus Kinase 3 - antagonists & inhibitors Male Middle Aged narrowband ultraviolet B nbUVB phototherapy Piperidines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Pyrroles - therapeutic use Retrospective Studies ruxolitinib Severity of Illness Index Skin Pigmentation tofacitinib Ultraviolet Therapy vitiligo Vitiligo - immunology Vitiligo - metabolism Vitiligo - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!